Moderna, Inc. - Common Stock (MRNA)

Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.

Investors who suffered losses on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 22, 2026 disclosure concerning Moderna, Inc.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.

Moderna, Inc. ("Moderna" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Moderna, Inc. (NASDAQ: MRNA), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Moderna, Inc. on October 22, 2026.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation #LBA1), were selected for an official ESMO Press Briefing and have been accepted for publication in The New England Journal of Medicine.

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, November 6, 2026 to report its third quarter 2026 financial results, and provide a corporate update.

Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event via webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END

A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers

CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19.

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END

A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated

Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth

FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026